Health
PharmAust continues to progress lead drug monepantel in treating canine and human cancers, COVID-19 – Small Caps
Six dogs have completed PharmAust’s (ASX: PAA) phase IIb trial evaluating its lead drug monepantel (MPL) in the most prevalent cancer in canines B-cell lymphoma….
Six dogs have completed PharmAusts (ASX: PAA) phase IIb trial evaluating its lead drug monepantel (MPL) in the most prevalent cancer in canines B-cell lymphoma.
During the March quarter, PharmAust revealed six dogs with stage four to five B-cell lymphoma had completed evaluation across five trial sites.
However, one dog was not in compliance with the trial process and was subsequently withdrawn.
PharmAust noted the remaining dogs side-effects were less than conventional anti-cancer drugs, with only…
-
Noosa News14 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News15 hours agoMotorcyclist dies in crash with truck
-
Noosa News16 hours agoSomerville House investigating after teachers’ dossier on students leaked
-
General21 hours agoSmall-town cleaner finds himself in legal battle with EnduroShield over product packaging